acs 2
 
bar

program

slides

  test

syllabus
bar
 
 

Cardiovascular Emergencies

New Dimensions and Critical Practice Advances
National Congress
Seatte, WA

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This symposium is designed for emergency medicine specialists, emergency medicine fellows, emergency medicine nurses, nurse practitioners (NPs) with EM concentration, physician assistants (PAs) with emergency medicine focus, prehospital care providers, cardiologists and cardiovascular specialists, critical care physicians and intensivists

Registration:

Enrollment for this webcast is complimentary, and clinicians are invited to attend this CME-certified symposium and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

rocheSupported by an independent educational grant from The Medicines Company, Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

Judd E. Hollander, MD
Grant/Research Support: Sanofi-Aventis, Biosite, Scios, The Medicines Company
Consultant: Sanofi-Aventis, Biosite, Scios, The Medicines Company
Speaker’s Bureau: Sanofi-Aventis, Biosite, Scios, The Medicines Company

Sunil Rao, MD, FACC
Grant/Research Support: Cordis
Consultant: Sanofi-Aventis, The Medicines Company
Speaker’s Bureau: Sanofi-Aventis, The Medicines Company, Cordis

Charles V. Pollack, MD, FACEP

Grant/Research Support: GlaxoSmithKline
Consultant: The Medicines Co., Schering-Plough, Sanofi-Aventis, BMS, Genentech
Speaker’s Bureau: Schering-Plough, Sanofi-Aventis, BMS, Genentech

Program Faculty:

Judd E. Hollander, MD
Professor and Clinical Research Director
Department of Emergency Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Sunil Rao, MD, FACC
Director of Interventional Cardiology
Veterans Administration Medical Center
Assistant Professor
Division of Cardiovascular Medicine
Duke University Medical Center
Durham, North Carolina

Charles V. Pollack Jr, MA, MD, FACEP, FAAEM

Chairman, Department of Emergency Medicine
Pennsylvania Hospital
Professor of Emergency Medicine
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Educational Objectives:

  • Learn to identify signs, symptoms, and prog nostic features of acute coronary syndrome and related cardiovascular emergencies.
  • Learn to assess and implement optimal pharma cologic interventions, especially antithrombotic therapy in the upstream setting, for patients presenting with manifestations of ACS and related cardiovascular disease emergencies.
  • Learn to characterize, identify, and evaluate the safety, efficacy, and side effects of myriad therapeutic options used for acute ischemic coronary syndromes including, aspirin, antiplatelet agents, direct thrombin inhibitors, UFH, LMWHs, and factor Xa inhibitors.
  • Learn to understand the specific advantages and potential disadvan tages of currently pharmacologic agents used to reduce ischemic and bleeding end points in the setting of cardiovascular emergencies.
  • Learn to identify the ideal properties of antithrombotic agents used to provide emergency- and cardiology-based care for ACS patients.
  • Learn to discuss and assess the impact that new trials and AHA/ACC Guidelines are likely to have on future management of patients with cardiovascular emergencies, including ACS.
  • As a result of this session, ED physicians will learn to apply national guidelines and expert, consensus-based recommendations in order to optimize emergency-based therapy of patients with ACS..

Disclaimer:

Copyright © 2007 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides

  test

syllabus
bar

YES, I have read the CME information statement

Copyright (c) 2007 All rights reserved


 
6

 

 

 

 

Key Program Topics Include:
Abciximab
ACC/AHA
ACS
ACUITY
Acute Coronary Syndromes
Adenosine
Albumin
Anticoagulants
Anticoagulation
Antiplatelet
SYNERGY
Aspirin
Bivalirudin
Bleeding
Cath Lab
Catheterization
Streams
CLARITY–TIMI 28
Class I
Class IIa
Class IIb








Class III
Clopidogrel
CPK-MB
CREDO
CRUSADE
Double-bolus t-PA
Early Invasive
Early Invasive Therapy
Echocardiogram
Emergency Department
enoxaparin
Eptifibatide
EXTRACT
Fibrinolysis
Fibrinolytics
Fondaparinux
GIK
GP IIb/IIIa
GP IIb/IIIa inhibition
GP IIb/IIIa Inhibitors
Guidelines
iClasses of

Recommendations
GUSTO
Hirudin
Initial Conservative
Initial Conservative Therapy
ischemic
LMWH
low-molecular-weight heparin
lytic
Magnesium
MI
Myocardial Infarction
Myoglobin
Net Clinical Benefit
nPA
NSTE ACS:
Risk Stratify
Chest Pain
NSTEMI
PCI
OASIS-5
Oral GP IIb/IIIa
Parenteral Antiplatelet Therapy
Pexulizamab
Primary End Point
PSGL
REPLACE 2
Revascularization
rPA
STEMI
SYNERGY
Thienopyridine
TIMI
TIMI 25
Tirofiban
TNK
Troponin
UA
UA/NSTEMI
UFH
unfractionated heparin
Unstable Angina
Upstream